1 year return (CAGR)
-28.65%
Mathios Refractories S.A. Exchange (AT, EUR)
MATHIO.AT
0.66
0.00 (0.00%)
Basic MaterialsBuilding Materials
Loading...
3 year return (CAGR)
-22.17%
5 year return (CAGR)
4.48%
10 year return (CAGR)
-0.15%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
6.48M
Price/Sales
0.85
Ent value
-
Price/Book
-
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 0.67 |
| Daily high | 0.67 |
| Daily low | 0.66 |
| Daily Volume | 1K |
| All-time high | 8900.00 |
| 1y analyst estimate | - |
| Beta | 0.54 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| MATHIO.AT | S&P500 | |
| Current price drop from All-time high | -99.99% | -0.58% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 25 Oct 2018 | 9 Mar 2009 |
| Avg drop from high | -97.53% | -10.68% |
| Avg time to new high | 474 days | 12 days |
| Max time to new high | 5172 days | 1805 days |
News
Klépierre (ENXTPA:LI) drew investor attention after its share price closed at €36.52, with recent returns mixed over the past month and the past 3 months for the European shopping mall specialist. Rec...
September 28, 2026
Space-based communications just had a spotlight moment as SpaceX’s Starship carried a fresh batch of Starlink satellites into orbit, and that test has many investors rethinking what satellite internet...
September 28, 2026
Gecina (ENXTPA:GFC) has drawn investor attention after recent trading left the stock flat on the day but down over the past month and the past 3 months, prompting closer scrutiny of its €4.7b valuatio...
September 27, 2026
On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological cond...
September 26, 2026
On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker’s board to improve oversight...
September 25, 2026
Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The deal gives Novartis worldwide rights to develop and c...
September 25, 2026
Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.
September 24, 2026
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically ...
September 24, 2026
While MSD has proven remigromig non-inferior to Lucentis in terms of efficacy in DME, questions around its tolerability remain.
September 24, 2026